Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

  title={Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours},
  author={K. L. Yim},
Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
8 Extracted Citations
34 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 34 references

A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs)

  • D. L. Reidy, E. Hollywood, M. Segal, L. Saltz
  • ASCO Meeting Abstracts,
  • 2010
Highly Influential
4 Excerpts

A phase II trial

  • J. C. Yao, C. Lombard-Bohas, +8 authors Daily oral everolimus activity in patients with metastat chemotherapy
  • J. Clin. Oncol. 28, 69–76
  • 2010
Highly Influential
14 Excerpts

Similar Papers

Loading similar papers…